多西他赛后是什么？
[What comes after docetaxel?].
作者信息
Ohlmann C-H, Stöckle M
机构信息
Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstrasse 1, 66421, Homburg/Saar, Deutschland.
出版信息
Urologe A. 2010 Jan;49(1):64-8. doi: 10.1007/s00120-009-2146-6.
Chemotherapy with docetaxel represents the standard first-line treatment in patients with castration-resistant prostate cancer (CRPC). In cases of progression after treatment with docetaxel no standard treatment recommendation exists since no treatment was able to show a survival benefit in clinical trials. This review focuses on available treatment options for patients with progressive CRPC and highlights promising treatments that are currently under investigation in clinical trials including abiraterone acetate and MDV3100.
多西他赛化疗是去势抵抗性前列腺癌（CRPC）患者的标准一线治疗方法。对于多西他赛治疗后病情进展的患者，目前尚无标准的治疗推荐，因为在临床试验中没有任何治疗方法能显示出生存获益。本综述重点关注进展性CRPC患者的现有治疗选择，并强调目前正在临床试验中研究的有前景的治疗方法，包括醋酸阿比特龙和MDV3100。
Zotero 插件